Ensysce Biosciences, Inc. — Form 8-K/A
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K/A
▼ Likely negative
significance 28/100
What the filing says
On August 5, 2026, Ensysce Biosciences completed acquisition of Cy Biopharma via two-step merger. Consideration: 282,122 shares of Series C Preferred Stock (convertible 1:1000 into common) to Cy equityholders. Concurrent private placement: 66,811 preferred shares for ~$21.5M gross proceeds. Cy also secured ~$17.1M convertible note pre-closing. Second tranche of ~$21.5M (75.615M common shares equivalent) contingent on clinical milestone. Cy is clinical-stage developer of CY200/CY201 (psilocybin/psilocin for CRPS); Ensysce expands from abuse-resistant opioids (PF614) into psychedelic therapies.
Why this rating
Material transaction for $5.3M company but laden with execution risk: going-concern doubt, Schedule I regulatory barriers, unproven psilocybin efficacy in CRPS, massive dilution (358M+ new shares post-conversion = ~95% ownership to insiders), Nasdaq delisting threat, contingent funding dependent on unmet clinical milestone.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.